1
|
Fu R, Chang R, Peng A, Feng C, Zhu W, Chen Y, Tian X, Wang R, Yan H, Jia D, Li J. Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes. Pharm Dev Technol 2024; 29:52-61. [PMID: 38230653 DOI: 10.1080/10837450.2024.2301763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Accepted: 01/01/2024] [Indexed: 01/18/2024]
Abstract
To solve the problem of resistance of tumor cells to TRAIL and the inevitable side effects of imatinib during treatment, we successfully prepared a kind of multifunctional liposome that encapsulated imatinib in its internal water phase and inserted TRAIL on its membrane in this study, which named ITLPs. The liposomes appeared uniform spherical and the particle size was approximately 150 nm. ITLPs showed high accumulation in TRAIL-resistance cells and HT-29 tumor-bearing mice model. In vitro cytotoxicity assay results showed that the killing activity of HT-29 cells treated with ITLPs increased by 50% and confirmed that this killing activity was mediated by the apoptosis pathway. Through mechanism studies, it was found that ITLPs arrested up to 32.3% of cells in phase M to exert anti-tumor effects. In vivo anti-tumor study showed that ITLPs achieved 61.8% tumor suppression and little toxicity in the HT-29 tumor-bearing mice model. Overall results demonstrated that codelivery of imatinib and TRAIL via liposomes may be a prospective method in the treatment of the TRAIL-resistance tumor.
Collapse
Affiliation(s)
- Rongrong Fu
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Rui Chang
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Andong Peng
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Changshun Feng
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Weifan Zhu
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Yi Chen
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Xue Tian
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Rui Wang
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Hui Yan
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Dianlong Jia
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Jun Li
- Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| |
Collapse
|
2
|
Lu X, Liu S, Han M, Yang X, Sun K, Wang H, Mu H, Du Y, Wang A, Ni L, Zhang C. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. Int J Pharm 2019; 560:126-135. [DOI: 10.1016/j.ijpharm.2019.02.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2018] [Revised: 01/23/2019] [Accepted: 02/05/2019] [Indexed: 01/08/2023]
|
3
|
Guarnieri M, Brayton C, Tyler BM. A Long-Term Study of a Lipid-Buprenorphine Implant in Rats. J Vet Med 2018; 2018:2616152. [PMID: 30112418 PMCID: PMC6077592 DOI: 10.1155/2018/2616152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Accepted: 06/24/2018] [Indexed: 11/17/2022] Open
Abstract
Animal models to study opiates are of growing interest. We have examined the short-term safety of buprenorphine implants in Fischer F344/NTac rats treated with excess doses of a cholesterol-triglyceride suspension of buprenorphine. A single injection of 0.65 mg/kg afforded clinically significant blood levels of analgesia for 3 days. Chemistry, hematology, coagulation, and urinalysis values with 2- to 10-fold excess doses of the drug-lipid suspension were within normal limits. Histopathology findings were unremarkable. The skin and underlying tissue surrounding the drug injection were unremarkable. Here we report the results of a long-term follow-up study of female rats injected with 0.65 and 1.3 mg/kg. The 14-month evaluation showed no abnormal findings that could be attributed to the drug or lipid suspension. These results confirm the safety of cholesterol-triglyceride carrier systems for subcutaneous drug delivery in laboratory animals and suggest that this model may be used to study long-term effects of opiate therapy.
Collapse
Affiliation(s)
- Michael Guarnieri
- Johns Hopkins School of Medicine, Department of Neurological Surgery, Baltimore, MD, USA
| | - Cory Brayton
- Johns Hopkins School of Medicine, Department of Molecular and Comparative Pathobiology, Baltimore, MD, USA
| | - Betty M. Tyler
- Johns Hopkins School of Medicine, Department of Neurological Surgery, Baltimore, MD, USA
| |
Collapse
|
4
|
Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats. J Vet Med 2017; 2017:3102567. [PMID: 28492060 PMCID: PMC5401735 DOI: 10.1155/2017/3102567] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2017] [Revised: 03/18/2017] [Accepted: 03/21/2017] [Indexed: 11/18/2022] Open
Abstract
A Target Animal Safety protocol was used to examine adverse events in male and female Fischer F344/NTac rats treated with increasing doses of a subcutaneous implant of a lipid suspension of buprenorphine. A single injection of 0.65 mg/kg afforded clinically significant blood levels of drug for 3 days. Chemistry, hematology, coagulation, and urinalysis values with 2- to 10-fold excess doses of the drug-lipid suspension were within normal limits. Histopathology findings were unremarkable. The skin and underlying tissue surrounding the drug injection were unremarkable. Approximately 25% of a cohort of rats given the excess doses of 1.3, 3.9, and 6.5 mg/kg displayed nausea-related behavior consisting of intermittent and limited excess grooming and self-gnawing. These results confirm the safety of cholesterol-triglyceride carrier systems for subcutaneous drug delivery of buprenorphine in laboratory animals and further demonstrate the utility of lipid-based carriers as scaffolds for subcutaneous, long-acting drug therapy.
Collapse
|
5
|
Franklin RK, Marcus SA, Talaat AM, KuKanich BK, Sullivan R, Krugner-Higby LA, Heath TD. A Novel Loading Method for Doxycycline Liposomes for Intracellular Drug Delivery: Characterization of In Vitro and In Vivo Release Kinetics and Efficacy in a J774A.1 Cell Line Model of Mycobacterium smegmatis Infection. Drug Metab Dispos 2015; 43:1236-45. [PMID: 26033620 DOI: 10.1124/dmd.115.063602] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Accepted: 06/01/2015] [Indexed: 01/10/2023] Open
Abstract
Doxycycline (doxy) is used in treating intracellular and extracellular infections. Liposomal (LE) antibiotics allow low-frequency dosing and extended efficacy compared with standard (STD) formulations. We developed a novel sulfuric acid-loading method for doxycycline liposomes (LE-doxy). We hypothesized that a single s.c. injection of LE-doxy would be detectable in serum for at least 2 weeks at concentrations equal to or better than STD-doxy and would be bactericidal in an in vitro Mycobacterium smegmatis infection of J774A.1 macrophage cells. Liposomes were encapsulated by sulfuric acid gradient loading, and release kinetics were performed in vitro and in vivo. LE-doxy made using 8.25 mg/ml doxycycline loaded for 24 hours achieved 97.77% capture in 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 43.87% in sphingomyelin (sphing). Rats were injected s.c. with 50 mg/kg LE-doxy or 5 mg/kg STD-doxy, and serial blood samples were collected. Pharmacokinetics were analyzed using high-performance liquid chromatography. Liver and injection site skin samples were collected at euthanasia (4 weeks postinjection). Minimal histologic tissue reactions occurred after injection of STD (nonliposomal), DPPC, or sphing-doxy. DPPC-doxy had slightly faster in vitro leakage than sphing liposomes, although both were detectable at 264 hours. The mean residence time for DPPC was the highest (111.78 hours), followed by sphing (56.00 hours) and STD (6.86 hours). DPPC and sphing-doxy were detectable at 0.2 μg/ml in serum at 336 hours postadministration. LE-doxy was not toxic to J774A.1 cells in vitro and produced inhibition of viable Mycobacterium smegmatis at 24 and 48 hours. LE-doxy will require further testing in in vivo infection models.
Collapse
Affiliation(s)
- Rebekah K Franklin
- Pharmacology, Clinical, Analytical, and Toxicological Services and the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas (B.K.K.); and Departments of Surgical Sciences (L.A.K.-H.), Pathobiological Sciences (R.S.), and Comparative Biosciences (A.M.T., S.A.M.); School of Veterinary Medicine (R.S.); School of Pharmacy (T.D.H.); and Research Animal Resources Center, University of Wisconsin, Madison, Wisconsin (R.K.F., L.A.K.-H., R.S.)
| | - Sarah A Marcus
- Pharmacology, Clinical, Analytical, and Toxicological Services and the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas (B.K.K.); and Departments of Surgical Sciences (L.A.K.-H.), Pathobiological Sciences (R.S.), and Comparative Biosciences (A.M.T., S.A.M.); School of Veterinary Medicine (R.S.); School of Pharmacy (T.D.H.); and Research Animal Resources Center, University of Wisconsin, Madison, Wisconsin (R.K.F., L.A.K.-H., R.S.)
| | - Adel M Talaat
- Pharmacology, Clinical, Analytical, and Toxicological Services and the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas (B.K.K.); and Departments of Surgical Sciences (L.A.K.-H.), Pathobiological Sciences (R.S.), and Comparative Biosciences (A.M.T., S.A.M.); School of Veterinary Medicine (R.S.); School of Pharmacy (T.D.H.); and Research Animal Resources Center, University of Wisconsin, Madison, Wisconsin (R.K.F., L.A.K.-H., R.S.)
| | - Butch K KuKanich
- Pharmacology, Clinical, Analytical, and Toxicological Services and the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas (B.K.K.); and Departments of Surgical Sciences (L.A.K.-H.), Pathobiological Sciences (R.S.), and Comparative Biosciences (A.M.T., S.A.M.); School of Veterinary Medicine (R.S.); School of Pharmacy (T.D.H.); and Research Animal Resources Center, University of Wisconsin, Madison, Wisconsin (R.K.F., L.A.K.-H., R.S.)
| | - Ruth Sullivan
- Pharmacology, Clinical, Analytical, and Toxicological Services and the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas (B.K.K.); and Departments of Surgical Sciences (L.A.K.-H.), Pathobiological Sciences (R.S.), and Comparative Biosciences (A.M.T., S.A.M.); School of Veterinary Medicine (R.S.); School of Pharmacy (T.D.H.); and Research Animal Resources Center, University of Wisconsin, Madison, Wisconsin (R.K.F., L.A.K.-H., R.S.)
| | - Lisa A Krugner-Higby
- Pharmacology, Clinical, Analytical, and Toxicological Services and the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas (B.K.K.); and Departments of Surgical Sciences (L.A.K.-H.), Pathobiological Sciences (R.S.), and Comparative Biosciences (A.M.T., S.A.M.); School of Veterinary Medicine (R.S.); School of Pharmacy (T.D.H.); and Research Animal Resources Center, University of Wisconsin, Madison, Wisconsin (R.K.F., L.A.K.-H., R.S.)
| | - Timothy D Heath
- Pharmacology, Clinical, Analytical, and Toxicological Services and the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas (B.K.K.); and Departments of Surgical Sciences (L.A.K.-H.), Pathobiological Sciences (R.S.), and Comparative Biosciences (A.M.T., S.A.M.); School of Veterinary Medicine (R.S.); School of Pharmacy (T.D.H.); and Research Animal Resources Center, University of Wisconsin, Madison, Wisconsin (R.K.F., L.A.K.-H., R.S.)
| |
Collapse
|
6
|
Abstract
It is important that veterinarians treating exotic companion mammals stay abreast of the latest developments relating to medications and drug delivery approaches for safety, efficacy and welfare issues. Sustained release formulations of commonly used drugs as well as newer routes for administration of therapeutic agents allow the veterinarian treating exotic companion mammals to reduce the stress associated with drug administration. Interactions can occur between vehicle and drugs when formulations are compounded, therefore research studies are warranted regarding potential problems associated with these formulations.
Collapse
Affiliation(s)
- Michelle G Hawkins
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, 2108 Tupper Hall, Davis, CA 95616, USA.
| |
Collapse
|